CDK4 and breast cancer: Moreover, adjuvant abemaciclib or ribociclib treatment has shown evident invasive disease‐free survival gain in patients with surgically resected stage II or III breast cancer [2, 3], further expanding the CDK4/6i indication to include approximately 60% of all patients with hormone receptor‐positive and HER2‐negative breast cancer [4], representing approximately 700 000 new cases worldwide.